

# CITATION REPORT

List of articles citing

Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events

DOI: 10.1016/j.jash.2018.03.008

Journal of the American Society of Hypertension, 2018, 12, 409-425.

**Source:** <https://exaly.com/paper-pdf/69374061/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
119	Arterial events in cancer patients-the case of acute coronary thrombosis. <b>2018</b> , 10, S4367-S4385		23
118	Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis. <b>2018</b> , 29, 381-388		5
117	Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials. <b>2018</b> , 38, 1109-1123		9
116	Management of VEGF-Targeted Therapy-Induced Hypertension. <b>2018</b> , 20, 68		15
115	Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies - part 1. <b>2018</b> , 17, 875-892		12
114	Anti-VEGF Signalling Mechanism in HUVECs by Melatonin, Serotonin, Hydroxytyrosol and Other Bioactive Compounds. <b>2019</b> , 11,		7
113	Supplementation With the Sialic Acid Precursor N-Acetyl-D-Mannosamine Breaks the Link Between Obesity and Hypertension. <b>2019</b> , 140, 2005-2018		20
112	Arterial hypertension in cancer: The elephant in the room. <b>2019</b> , 281, 133-139		29
111	A study of atherothrombotic biomarkers in welders. <b>2019</b> , 92, 1023-1031		7
110	Long-term cardiovascular effects of vandetanib and pazopanib in normotensive rats. <b>2019</b> , 7, e00477		2
109	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. <b>2019</b> , 96, 555-567		25
108	Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics. <b>2019</b> , 202, 18-31		19
107	Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. <b>2019</b> , 121, 109-116		23
106	Endothelial ERK1/2 signaling maintains integrity of the quiescent endothelium. <b>2019</b> , 216, 1874-1890		29
105	Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers. <b>2019</b> , 39, 248-260		7
104	STRIP2 silencing inhibits vascular smooth muscle cell proliferation and migration via P38-AKT-MMP-2 signaling pathway. <b>2019</b> , 234, 22463-22476		6
103	Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension. <b>2019</b> , 115, 904-914		33

102	A Novel Discovery: Holistic Efficacy at the Special Organ Level of Pungent Flavored Compounds from Pungent Traditional Chinese Medicine. <b>2019</b> , 20,	5
101	Common Vascular Toxicities of Cancer Therapies. <b>2019</b> , 37, 365-384	3
100	Scutellarin Prevents Angiogenesis in Diabetic Retinopathy by Downregulating VEGF/ERK/FAK/Src Pathway Signaling. <b>2019</b> , 2019, 4875421	19
99	Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib. <b>2019</b> , 19, 382-387	9
98	Effects of Antiangiogenic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer. <b>2018</b> , 11,	5
97	Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies. <b>2019</b> , 42, 159-179	13
96	Selective ETA vs. dual ETA/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats. <b>2020</b> , 116, 1779-1790	13
95	Development of a thrombus in the superior mesenteric artery associated with sequential therapy with tyrosine kinase inhibitors for hepatocellular carcinoma. <b>2020</b> , 13, 247-251	1
94	Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?. <b>2020</b> , 19, 223-228	1
93	Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <b>2020</b> , 12,	3
92	Management of Patients with Acute Coronary Syndrome and Cancer. <b>2020</b> , 22, 159	2
91	Microcirculation in Cardiovascular Diseases. <b>2020</b> ,	
90	Sunitinib-induced oxidative imbalance and retinotoxic effects in rats. <b>2020</b> , 257, 118072	4
89	Cardiomyopathies and Arrhythmias Induced by Cancer Therapies. <b>2020</b> , 8,	5
88	Angiogenesis in Patients with Chronic Heart Failure: Focus on Endothelial Vascular Growth Factor, Pentraxin-3 and Transforming Growth Factor Beta. <b>2020</b> , 16, 439-448	
87	VEGF-A in Cardiomyocytes and Heart Diseases. <b>2020</b> , 21,	35
86	The Role of Biomarkers to Evaluate Cardiotoxicity. <b>2020</b> , 21, 79	4
85	Bioinformatics and Molecular Insights to Anti-Metastasis Activity of Triethylene Glycol Derivatives. <b>2020</b> , 21,	3

84	Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE. <b>2020</b> , 43, 971-980	5
83	The hypertensive effect of sorafenib is abolished by sildenafil. <b>2020</b> , 6, 7	2
82	Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab. <b>2020</b> , 9,	8
81	Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. <b>2020</b> , 70, 480-504	16
80	Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase III FRESCO Trial. <b>2020</b> , 37, 4585-4598	1
79	Neural Control of Immunity in Hypertension: Council on Hypertension Mid Career Award for Research Excellence, 2019. <b>2020</b> , 76, 622-628	12
78	Retooling Cancer Nanotherapeutics Entry into Tumors to Alleviate Tumoral Hypoxia. <b>2020</b> , 16, e2003000	19
77	The updated landscape of tumor microenvironment and drug repurposing. <b>2020</b> , 5, 166	170
76	Cardiovascular and Pulmonary Challenges After Treatment of Childhood Cancer. <b>2020</b> , 67, 1155-1170	3
75	Cardiovascular risk profile and events before and after treatment with anti-VEGF drugs in the setting of a structured cardio-oncologic program. <b>2021</b> , 28, e38-e40	2
74	Vascular toxic effects of cancer therapies. <b>2020</b> , 17, 503-522	55
73	Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. <b>2020</b> , 17, 474-502	126
72	Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity. <b>2020</b> , 13, 377-389	7
71	Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy. <b>2020</b> , 18, e457-e472	1
70	Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect. <b>2021</b> , 10, 164-172	4
69	Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin. <b>2021</b> , 127, 938-945	5
68	Cardiotoxic effects of angiogenesis inhibitors. <b>2021</b> , 135, 71-100	13
67	Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature. <b>2021</b> , 28, 661-670	1

66	Targeted drug delivery strategies for precision medicines.. <b>2021</b> , 6, 351-370	86
65	Neurological Complications of Targeted Therapies and Immunotherapies for Cancer. <b>2021</b> , 23, 1	2
64	The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy. <b>2021</b> , 18, 565-580	28
63	Sorafenib not only impairs endothelium-dependent relaxation but also promotes vasoconstriction through the upregulation of vasoconstrictive endothelin type B receptors. <b>2021</b> , 414, 115420	3
62	Microvascular Structural Alterations in Cancer Patients Treated With Antiangiogenic Drugs. <b>2021</b> , 8, 651594	2
61	Clinical Efficacy and Safety of Angiogenesis Inhibitors: Sex Differences and Current Challenges. <b>2021</b> ,	4
60	Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature. <b>2021</b> , 26, 526-534	2
59	Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. <b>2021</b> , 128, 1040-1061	14
58	Axitinib Induces and Aggravates Hypertension Regardless of Prior Treatment With Tyrosine Kinase Inhibitors. <b>2021</b> , 3, 234-240	2
57	[Cancer, onco-haematological treatment and cardiovascular toxicity]. <b>2021</b> , 38, 72-82	0
56	Cancer Therapy-Associated Thrombosis. <b>2021</b> , 41, 1291-1305	16
55	The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review. <b>2021</b> , 1	7
54	Coronary artery disease in patients with cancer: challenges and opportunities for improvement. <b>2021</b> , 36, 597-608	0
53	Tumors modulate fenestrated vascular beds and host endocrine status. <b>2021</b> , 41, 1952-1965	0
52	Human Platelets Take up Anti-VEGF Agents. <b>2021</b> , 2021, 8811672	1
51	Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?. <b>2021</b> , 135, 1649-1668	3
50	The Provocative Roles of Platelets in Liver Disease and Cancer. <b>2021</b> , 11, 643815	1
49	Half-Moon-shaped Aortic Arch Thrombosis Induced by Lenvatinib. <b>2021</b> , 300, 289	0

- 48 What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist?. **2021**, 33, 483-493 2
- 47 Risk of Thrombo-Embolic Events in Ovarian Cancer: Does Bevacizumab Tilt the Scale? A Systematic Review and Meta-Analysis. **2021**, 13, 0
- 46 Does bevacizumab increase joint pain in patients with cancer? Results of the prospective observational BEVARTHRALGIA study. **2021**, 87, 533-541 2
- 45 COVID-19 As An Endothelial Disease and Its Relationship to Vascular Endothelial Growth Factor (VEGF) and Iodide. 9
- 44 Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. **2021**, 1-10 0
- 43 The Importance of Primary Care in Cardio-Oncology. **2021**, 22, 107
- 42 High pressure as a side effect of drugs. **2019**, 33, 25-28
- 41 Recurrent Coronary Artery Vasospasm in a Patient with Hepatocellular Carcinoma Treated with Sorafenib: a Case Report and Literature Review. **2020**, 20, 67-71
- 40 Cardiovascular Effects of Anti-angiogenic Drugs. **2020**, 165-171
- 39 The Current Status and Future Perspective of Cardio-Oncology. **2020**, 109, 819-826
- 38 Hypoxia signaling and oxygen metabolism in cardio-oncology.. **2022**, 165, 64-75 1
- 37 VEGF: A KEY PLAYER NOT ONLY IN MACULAR DEGENERATION. A REVIEW. **2020**, 76, 1-3
- 36 Anti-VEGF Effect of Bioactive Indolic Compounds and Hydroxytyrosol Metabolites.. **2022**, 11, 0
- 35 Dissecting the Polygenic Basis of Primary Hypertension: Identification of Key Pathway-Specific Components.. **2022**, 9, 814502 0
- 34 Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer.. **2022**, 9, 727487 3
- 33 Tumors Modulate the Systemic Vascular Response to Anti-angiogenic Therapy.. **2022**,
- 32 Hypertension: Potential Player in Cardiovascular Disease Incidence in Preeclampsia.. **2022**, 22, 391
- 31 Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.. **2022**, JCO2101806 1

30	Early biomarkers of nephrotoxicity associated with the use of anti-VEGF drugs. <b>2022</b> , 16,	0
29	Onco-hypertension: An Emerging Specialty.. <b>2021</b> , 28, 477-489.e1	1
28	Physiology of Continuous-Flow Left Ventricular Assist Device Therapy.. <b>2021</b> , 12, 2731-2767	1
27	Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage.. <b>2022</b> ,	0
26	(Physiology of Continuous-flow Left Ventricular Assist Device Therapy. Translation of the document prepared by the Czech Society of Cardiology). <b>2022</b> , 64, 89-132	
25	Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.. <b>2022</b> , 1	1
24	Study of the Association between VEGF Polymorphisms and the Risk of Coronary Artery Disease in Koreans. <b>2022</b> , 12, 761	
23	Risks and management of hypertension in cancer patients undergoing targeted therapy: a review.. <b>2022</b> , 28, 14	0
22	Vascular endothelial growth factor-tyrosine kinase inhibitors: Novel mechanisms, predictors of hypertension and management strategies. <b>2022</b> , 17, 100144	1
21	Oncologic emergencies and urgencies: A comprehensive review.	2
20	Intracellular Signaling Pathways Mediating Tyrosine Kinase Inhibitor Cardiotoxicity. <b>2022</b> ,	2
19	Vascular disease prevention: Before cancer therapy. <b>2023</b> , 80-91	
18	Hypertension and renal disease during anti-cancer therapies. <b>2023</b> , 185-199	
17	Vascular disease prevention and management after cancer therapy. <b>2023</b> , 264-270	
16	Cardiovascular complication from cancer therapy. <b>2022</b> , 165-193	
15	Myocardial Ischemia Related to Common Cancer TherapyPrevention Insights. <i>Life</i> , <b>2022</b> , 12, 1034	3 0
14	Urinary biomarkers of kidney injury in patients treated with anti-VEGF drugs. <b>2022</b> , 94, 725-730	
13	Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer. <b>2022</b> , 132,	2

- 12 On-Target Side Effects of Targeted Therapeutics of Cancer. 28,
- 11 Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost. **2022**, 23, 14121
- 10 Lipotoxicity, glucotoxicity and some strategies to protect vascular smooth muscle cell against proliferative phenotype in metabolic syndrome. **2023**, 172, 113546
- 9 Onconephrology 2022: An Update. 10.34067/KID.0001582022
- 8 Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association.
- 7 Efficacy and Toxicity of Anti-Vascular Endothelial Growth Receptor Tyrosine Kinase Inhibitors in Patients with Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. **2023**,
- 6 Arterial hypertension and anticancer drug therapy: pathophysiological relationships and clinical significance. **2023**, 5-10
- 5 Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies.
- 4 Cardiovascular Toxicity Induced by Vascular Endothelial Growth Factor Inhibitors. **2023**, 13, 366
- 3 Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension Mechanisms and Mitigation. **2023**, 80, 685-710
- 2 The mechanism and treatment of targeted anti-tumour drugs induced cardiotoxicity. **2023**, 117, 109895
- 1 Preexisting hypertension and cancer therapy: evidence, pathophysiology, and management recommendation.